CAR-T Long Term Follow Up (LTFU) Study
NCT02445222
Recruiting
Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector per... Read More
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
08/15/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +108 locations
Conditions: Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Register for Updates
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150
Recruiting
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: UCSF Fresno, Clovis, California +238 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764
Recruiting
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Arkansas Urology, Little Rock, Arkansas +122 locations
Conditions: Non-Muscle Invasive Bladder Neoplasms
Register for Updates
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277
Recruiting
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the o... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/15/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +72 locations
Conditions: Obesity, Weight Gain
Register for Updates
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
NCT05083182
Recruiting
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
08/15/2025
Locations: Childrens Hospital Los Angeles, Los Angeles, California +49 locations
Conditions: Arthritis, Juvenile
Register for Updates
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357
Recruiting
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1),... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: The Oncology Institute of Hope and Innovation, Cerritos, California +79 locations
Conditions: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Register for Updates
Developing an Intervention to Help Nurses Improve Sexual Healthcare in Men With Inflammatory Bowel Disease
NCT06562751
Recruiting
Inflammatory Bowel Disease (IBD) is a chronic, relapsing and remitting disease that can greatly impact health and personal well-being. Sexual health, relationships and intimacy have been raised as key concerns for those living with the disease. Men's sexual health and well-being has been identified as a neglected area. This study will lead to the development of an intervention that will help nurses to improve the assessment and care of the sexual health and well-being needs of men with IBD.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Sarah Ma, York, North Yorkshire
Conditions: Inflammatory Bowel Diseases
Register for Updates
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: IMMUNOe Health and Research Centers, Centennial, Colorado +91 locations
Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Register for Updates
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236
Recruiting
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Clovis Community Medical Center, Clovis, California +236 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
NCT06799533
Recruiting
This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. The study will have 3 parts. Part A and B of the study will find out how much PF-08046031 should be given to participants. Part C will use the information from Parts A and B to see if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate, Los Angeles, California +12 locations
Conditions: Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
Register for Updates
A Study of Daratumumab
NCT05438043
Recruiting
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/14/2025
Locations: University of Miami Sylvester Cancer Center, Miami, Florida +75 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095
Recruiting
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +152 locations
Conditions: Fistulizing Crohns Disease, Perianal Crohns Disease
Register for Updates